Thread: Strong Buy IBT.V - Ibex Technologies Inc.
View Single Post
Old 12-17-2015, 12:05 PM   Nav to Top 
JonnyR512
Senior Trader
 
JonnyR512's Avatar
 
Join Date: Jul 2009
Location: N/A
Posts: 1,343
Favorites: AXM, KUB
Rep Power: 185
Reputation: 168
JonnyR512 has a spectacular aura aboutJonnyR512 has a spectacular aura about
Default IBT.V - Ibex Technologies Inc.

I usually have a full due diligence report to post, but unfortunately we will have to wait for that until IBT releases their financials on Sedar. In the meantime I will use year end results, mixed with the Q1 news release that came out today.

IBT.V is a inexpensive biotech that looks to have turned the corner here in terms of probability and growth. Their year end results show a cash position of over $2 million, $6.38 million in assets and $1.7 million in liabilities. There are only 24.7 million common shares, of which 37% is held by insiders. In fact, two weeks ago the CEO purchased 246,000 shares on the open market which is 1% of the entire float. The company ended 2015 with a $210,000 net income and just today announced a $360,000 net income which means things are starting to grow rapidly. Last year IBT.V did $3.5 million in revenue total and just in Q1 2016 they did half of that amount. As well, sales are in US dollar, leveraging the company. Below is the news release from today:

IBEX earns $360,206 in fiscal Q1

2015-12-17 06:21 MT - News Release

Mr. Paul Baehr reports

IBEX REPORTS FIRST QUARTER FISCAL 2016 RESULTS

IBEX Technologies Inc. has released its financial results for the quarter ended Oct. 31, 2015.

"We are pleased to report an excellent quarter and start to the 2016 fiscal year. Net profit and working capital were up significantly over year ago, driven by lower operating costs and a significant increase in sales," said Paul Baehr, IBEX president and chief executive officer. "We continue to forecast a positive cash flow for the year; however, quarter-to-quarter profitability will vary significantly due the large variations in customer order patterns."

First quarter fiscal 2016 financial results

Sales for the quarter ended Oct. 31, 2015, totalled $1,414,875 compared with $627,447 in the same period of the prior year. Sales were up by $555,832 in the company's IBEX Pharma subsidiary and by $231,596 in its bioresearch products subsidiary. This increase in sales versus the previous year is primarily due to the quarter-to-quarter fluctuation in customer orders, rather than a sustained increase in sales.

The company sustained net earnings of $360,206, as compared with a net loss of $253,708 in the year-ago period. The favourable change in earnings traced mainly to the sales increase of $787,428 offset by the negative impact of inventory allocation of $194,166.

FINANCIAL SUMMARY FOR THE QUARTERS ENDED

Oct. 31, Oct. 31,
2015 2014

Revenues $1,414,875 $627,447
Earnings (loss) before interest, tax,
depreciation and amortization $460,302 ($161,642)
Depreciation $88,637 $84,137
Net earnings (loss) $360,206 ($253,708)
Earnings (loss) per share $0.01 ($0.01)

Cash and equivalents increased by $551,864 during the quarter ended Oct. 31, 2015, as compared with the year ended July 31, 2015. Net working capital increased by $436,764 during the quarter ended Oct. 31, 2015, as compared with the year ended July 31, 2015.

Looking forward

The company sees an improving picture and expects to be cash positive in the 2016 fiscal year if current customer purchase projections hold, and if the company continues to benefit from the favourable U.S./Canadian dollar exchange rate.

Management believes that the company has sufficient funds to meet its obligations and planned expenditures for the ensuing 12 months as they fall due. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period.

We seek Safe Harbor.

© 2015 Canjex Publishing Ltd. All rights reserved.
JonnyR512 is offline   Rate this post Yes | No Reply With Quote